# US 2020/0165182 A1 · Indene derivatives and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2020/0165182 A1
- Document ID: US20200165182A1
- Status: Published application
- Kind: A1
- Application number: 16/633,464
- Filed: 2018-08-29
- Published: 2020-05-28
- Earliest claimed: 2017-08-31
- Assignees: MUSC Foundation for Research Development
- Applicants: Musc Foundation for Research Development
- Inventors: Nathan G. DOLLOFF; Reeder M. ROBINSON; Allen B. REITZ; Haiyan BIAN
- Web page: https://patentgrep.com/patent/US20200165182A1

## CPC

- C07D 317/70: condensed with ring systems containing two or more relevant rings
- A61P 35/00: Antineoplastic agents
- C07C 39/38: with at least one hydroxy group on a condensed ring system containing two rings
- C07C 39/42: containing six-membered aromatic rings and other rings
- C07C 43/225: containing halogen
- C07C 49/255: containing ether groups, [IMAGE cpc-sch-C07C-0958.gif] groups,[IMAGE cpc-sch-C07C-0959.gif] groups, or[IMAGE cpc-sch-C07C-0960.gif] groups
- C07C 59/72: containing six-membered aromatic rings and other rings
- C07C 61/29: having a carboxyl group bound to a condensed ring system
- C07C 62/32: containing hydroxy or O-metal groups
- C07C 65/11: with carboxyl groups on a condensed ring system containing two rings
- C07C 69/67: of saturated acids
- C07C 69/708: Ethers
- C07C 69/712: the hydroxy group of the ester being etherified with a hydroxy compound having the hydroxy group bound to a carbon atom of a six-membered aromatic ring
- C07C 69/757: having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, [IMAGE cpc-sch-C07C-0958.gif] groups,[IMAGE cpc-sch-C07C-0959.gif] groups, or[IMAGE cpc-sch-C07C-0960.gif] in the acid moiety
- C07C 233/02: having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
- C07C 233/58: having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
- C07C 235/34: having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C 235/40: having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
- C07D 263/52: condensed with carbocyclic rings or ring systems
- C07D 317/52: Radicals substituted by halogen atoms or nitro radicals
- C07D 319/14: condensed with carbocyclic rings or ring systems
- C07C 2601/14: The ring being saturated
- C07C 2602/08: the other ring being five-membered, e.g. indane
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS

## Abstract

The present invention relates to compounds of formula (I): including any stereochemically isomeric form thereof, or pharmaceutically acceptable salts thereof, for the treatment of, for example, cancer.

## Claims

### Claim 1

A compound of formula (I):
wherein:
R1 and R2, independently of each other, are hydrogen, hydroxyl, alkyl, alkoxy, methoxy-acetate, phosphate, valine, Gly-Ser, —OC(O)CH2OC(O)CH3, —OC(O)CH2OCH3, —OCH2C(O)C(CH3)3, —OCH2C(O)NH2 or —OCH2C(O)OH; or R1 and R2, together with the carbon atoms to which they are attached, form a 5 to 6-membered ring with one or two ring carbons replaced independently by oxygen or nitrogen;
R3 is hydrogen, hydroxyl, halogen, cyano, —COOH, —C(O)NH2, —C(O)CH2CH3, —C(O)-alkoxy, alkyl, alkoxy, halo-lower alkyl, carboxyl, amide, ester or nitrile; and
R4 is alkyl or alkenyl, said alkyl or alkenyl optionally mono or bi-substituted independently with hydrogen, halogen, hydroxyl, —OCH2-phenyl, cycloalkyl, —OCH2-halophenyl or —OCH2— phenylhaloalkyl,
or a pharmaceutically acceptable salt thereof.

### Claim 2 (depends on 1)

The compound according to claim 1, wherein R1 and R2, independently of each other, are hydrogen, hydroxyl, alkyl, alkoxy, methoxy-acetate, phosphate, valine, Gly-Ser, —OC(O)CH2OC(O)CH3, —OC(O)CH2OCH3, —OCH2C(O)C(CH3)3, —OCH2C(O)NH2 or —OCH2C(O)OH.

### Claim 3 (depends on 1)

The compound according to claim 1, wherein R1 and R2, together with the carbon atoms to which they are attached, form a 5 to 6-membered ring with one or two ring carbons replaced independently by oxygen or nitrogen.

### Claim 4 (depends on 1)

The compound according to claim 1, wherein R1 is hydroxyl.

### Claim 5 (depends on 1)

The compound according to claim 1, wherein R2 is hydroxyl.

### Claim 6 (depends on 1)

The compound according to claim 1, wherein both R1 and R2 are hydroxyl.

### Claim 7 (depends on 1)

The compound according to claim 1, wherein R1 is alkoxy.

### Claim 8 (depends on 1)

The compound according to claim 1, wherein R2 is alkoxy.

### Claim 9 (depends on 1)

The compound according to claim 1, wherein both R1 and R2 are alkoxy.

### Claim 10 (depends on 1)

The compound according to claim 1, wherein R3 is hydrogen, hydroxyl, halogen, cyano, —COOH, —C(O)NH2, —C(O)CH2CH3, —C(O)-alkoxy, alkyl, alkoxy, halo-lower alkyl, carboxyl, amide, ester or nitrile.

### Claim 11 (depends on 1)

The compound according to claim 1, wherein R3 is amide.

### Claim 12 (depends on 1)

The compound according to claim 1, wherein R3 is —CF3.

### Claim 13 (depends on 1)

The compound according to claim 1, wherein R4 is alkenyl.

### Claim 14 (depends on 1)

The compound according to claim 1, wherein R4 is alkenyl optionally mono or bi-substituted independently with hydrogen, halogen, hydroxyl, —OCH2-phenyl, cycloalkyl, —OCH2— halophenyl or —OCH2-phenylhaloalkyl.

### Claim 15

A compound, wherein said compound is:
or a pharmaceutically acceptable salt thereof.

### Claim 16 (depends on 1)

A pharmaceutical composition, comprising a therapeutically effective amount of a compound according to claim 1, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

### Claim 17 (depends on 1)

A method for the treatment of cancer, comprising the step of administering to a patient in need thereof a therapeutically effective amount of a compound according to claim 1, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

### Claim 18 (depends on 1)

A method for the treatment of multiple myeloma, comprising the step of administering to a patient in need thereof a therapeutically effective amount of a compound according to claim 1, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

### Claim 19 (depends on 1)

A method for enhancing the activity of proteasome and/or HDAC inhibitors, comprising the step of administering to a patient in need thereof a therapeutically effective amount of a compound according to claim 1, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

### Claim 20 (depends on 1)

A method for enhancing the activity of proteasome and/or HDAC inhibitors during treatment of multiple myeloma, comprising the step of administering to a patient in need thereof a therapeutically effective amount of a compound according to claim 1, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

### Claim 21 (depends on 15)

A pharmaceutical composition, comprising a therapeutically effective amount of a compound according to claim 15, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

### Claim 22 (depends on 15)

A method for the treatment of cancer, comprising the step of administering to a patient in need thereof a therapeutically effective amount of a compound according to claim 15, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

### Claim 23 (depends on 15)

A method for the treatment of multiple myeloma, comprising the step of administering to a patient in need thereof a therapeutically effective amount of a compound according to claim 15, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

### Claim 24 (depends on 15)

A method for enhancing the activity of proteasome and/or HDAC inhibitors, comprising the step of administering to a patient in need thereof a therapeutically effective amount of a compound according to claim 15, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

### Claim 25 (depends on 15)

A method for enhancing the activity of proteasome and/or HDAC inhibitors during treatment of multiple myeloma, comprising the step of administering to a patient in need thereof a therapeutically effective amount of a compound according to claim 15, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
